FDA warns Evolus over misleading Instagram claims about Jeuveau
read at raps ↗RegulatoryNegative
The FDA's Office of Prescription Drug Promotion sent an untitled warning letter to Evolus, the maker of the injectable cosmetic product Jeuveau.
The letter says the company exaggerated the drug’s efficacy in social media posts and blurred the distinction between a prescription-only medication and over-the-counter cosmetics on Instagram.
Evolus will need to correct the promotional material to comply with FDA regulations, and the agency may take further action if the issues are not resolved.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “FDA admonishes Evolus for ‘false and misleading’ social media claims”
read at raps ↗
comments(0)
5-min edit window · permanent after that